Please login to the form below

Not currently logged in
Email:
Password:

BMS to buy Amira Pharmaceuticals

Bristol-Myers Squibb is to purchase inflammatory and fibrotic disease specialists Amira Pharmaceuticals in an acquisition potentially worth $475m

Bristol-Myers Squibb (BMS) is to purchase inflammatory and fibrotic disease specialists Amira Pharmaceuticals in an acquisition potentially worth $475m.

California-based Amira will receive $325m in upfront payments, with additional milestones totalling $150m.

Once the deal is complete, BMS will have access to Amira's fibrosis programme, including the investigative drug AM152, which is about to enter phase II clinical development.

Amira also has a preclinical programme for autotoxin – an enzyme associated with tumours.

BMS said it will retain Amira's scientists working on these projects.

Elliott Sigal, executive vice president, chief scientific officer and president, Research and Development at BMS, described fibrotic diseases as an area of "high unmet medical need." The Amira acquisition part of the company's plans to diversify its pipeline, he added.

25th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics